Thursday, 24 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 16, 2026

Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider

View original at globenewswire.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Asia Pacific is expected to grow at the fastest CAGR from 2026-2033 in the Uterine Fibroid Market

    80% confidence
  • Minimally Invasive Procedures is expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence
  • Laparoscopic Surgery dominated with 36.58% market share in 2025

    80% confidence
  • Healthcare expenditures in developing regions have grown by an approximate 45% over the last decade

    80% confidence
  • Asia Pacific is expected to grow at the fastest CAGR from 2026-2033 in the Uterine Fibroid Market

    80% confidence
  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence
  • Submucosal Fibroids dominated with 36.24% market share in 2025

    80% confidence
  • Laparoscopic Surgery dominated with 36.58% market share in 2025

    80% confidence
  • Asia Pacific is expected to grow at the fastest CAGR from 2026-2033 in the Uterine Fibroid Market

    80% confidence
  • The U.S. Uterine Fibroid Market size was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% during 2026-2033

    80% confidence
  • North America is predicted to hold a 45.32% market share in 2025 for uterine fibroids

    80% confidence
  • Hospitals & Clinics dominated with 47.49% in 2025 due to their advanced infrastructure and specialized gynecological care

    80% confidence
  • African American women have a high risk of uterine fibroids, occurring at a younger age with severe symptoms compared to other ethnicities

    80% confidence
  • Surgical Procedures dominated with 38.45% market share in 2025

    80% confidence
  • Submucosal Fibroids dominated with 36.24% market share in 2025

    80% confidence
  • Healthcare expenditures in developing regions have grown by an approximate 45% over the last decade

    80% confidence
  • North America is predicted to hold a 45.32% market share in 2025 for uterine fibroids

    80% confidence
  • Submucosal Fibroids dominated with 36.24% in 2025 due to their high prevalence and significant symptom severity

    80% confidence
  • African American women have a high risk of uterine fibroids, occurring at a younger age with severe symptoms compared to other ethnicities

    80% confidence
  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033

    80% confidence
  • North America is predicted to hold a 45.32% market share in 2025 for uterine fibroids

    80% confidence
  • Minimally invasive techniques including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound have seen adoption rates rise by more than 60% in the past five years

    80% confidence
  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence
  • Minimally Invasive Procedures is expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence
  • Intramural Fibroids is expected to grow at the fastest CAGR of 8.20% from 2026 to 2033

    80% confidence
  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence
  • The U.S. Uterine Fibroid Market size was valued at USD 1.78 Billion in 2025E and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% during 2026-2033

    80% confidence
  • Hospitals & Clinics dominated with 47.49% market share in 2025

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider — Source | Via News | ViaNews EU